Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones
Department of Biochemistry and Molecular Pharmacology
Anti-HIV Agents; Binding Sites; Crystallography, X-Ray; Drug Design; Drug Resistance, Multiple, Viral; HIV Protease Inhibitors; HIV-1; Humans; *Models, Molecular; Molecular Sequence Data; Molecular Structure; Mutation; Oxazolidinones; Stereoisomerism; Structure-Activity Relationship
Biochemistry, Biophysics, and Structural Biology | Microbiology
A series of new HIV-1 protease inhibitors with the hydroxyethylamine core and different phenyloxazolidinone P2 ligands were designed and synthesized. Variation of phenyl substitutions at the P2 and P2' moieties significantly affected the binding affinity and antiviral potency of the inhibitors. In general, compounds with 2- and 4-substituted phenyloxazolidinones at P2 exhibited lower binding affinities than 3-substituted analogues. Crystal structure analyses of ligand-enzyme complexes revealed different binding modes for 2- and 3-substituted P2 moieties in the protease S2 binding pocket, which may explain their different binding affinities. Several compounds with 3-substituted P2 moieties demonstrated picomolar binding affinity and low nanomolar antiviral potency against patient-derived viruses from HIV-1 clades A, B, and C, and most retained potency against drug-resistant viruses. Further optimization of these compounds using structure-based design may lead to the development of novel protease inhibitors with improved activity against drug-resistant strains of HIV-1.
DOI of Published Version
J Med Chem. 2010 Nov 11;53(21):7699-708. Link to article on publisher's site
Journal of medicinal chemistry
Ali, Akbar; Reddy, G. S. Kiran Kumar; Nalam, Madhavi N. L.; Anjum, Saima G.; Cao, Hong; Schiffer, Celia A.; and Rana, Tariq M., "Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones" (2010). Biochemistry and Molecular Pharmacology Publications and Presentations. 137.